专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

141. 发明申请

WO2015179779A1 GENOMIC INSTABILITY MARKERS IN FANCONI ANEMIA 审中-公开
标题翻译： FANCONI ANEMIA的基因组不稳定性标记
公开(公告)号：WO2015179779A1
公开(公告)日：2015-11-26
申请号：PCT/US2015/032204
申请日：2015-05-22
申请人： CHILDREN'S HOSPITAL MEDICAL CENTER
发明人： WELLS, Susanne, I. , SETCHELL, Kenneth, D.R. , ROMICK-ROSENDALE, Lindsey , ZHANG, Wujuan , ZHOA, Xueheng
IPC分类号： C12Q1/68 , C40B30/00 , C40B30/10 , C40B40/12
CPC分类号： A61K38/465 , A61K31/445 , A61K31/451 , A61K47/26 , C12N15/113 , C12N2310/14 , C12Q1/6886 , G01N33/57426 , G01N33/92 , G01N2800/22
摘要： Markers for genomic instability in Fanconi Anemia (FA) and other pathologies for therapeutic and diagnostic uses. In one embodiment, glycosphingolipid metabolism is altered in the FA deficient squamous cell carcinoma (SCC) cells, based on analysis of a metabolomics/lipidomics platform. The data indicated ganglioside metabolism was important in FA patients' susceptibility to SCC progression.
摘要翻译：在Fanconi贫血（FA）和其他病理学治疗和诊断用途的基因组不稳定性的标记。在一个实施方案中，基于代谢组学/脂质组学平台的分析，在FA缺陷型鳞状细胞癌（SCC）细胞中改变了鞘糖脂代谢。数据显示神经节苷脂代谢在FA患者对SCC进展的敏感性中是重要的。

142. 发明申请

WO2015143400A1 PHOSPHOLIPASE C GAMMA 2 AND RESISTANCE ASSOCIATED MUTATIONS 审中-公开
标题翻译：磷脂酶GAMMA 2和电阻相关突变
公开(公告)号：WO2015143400A1
公开(公告)日：2015-09-24
申请号：PCT/US2015/021871
申请日：2015-03-20
申请人： PHARMACYCLICS, INC.
发明人： BYRD, John, C. , WOYACH, Jennifer, A.
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6886 , A61K31/519 , C12Q2600/106 , C12Q2600/156 , G01N33/57426 , G01N2333/916 , G01N2800/52
摘要： Described herein is a mutation that confers resistance to the treatment with a BTK inhibitor. Described herein is a modified PLCy2 polypeptide that is modified at amino acid position 742, 845, or 1140 and the modified PLCy2 polypeptide exhibits decreased inhibition (e.g., resistance) to a covalent and/or irreversible BTK inhibitor. Described herein are diagnostic methods for detecting the modified polypeptide and nucleic acid encoding the modified polypeptide and applications of the methods thereof. Described herein are compositions, combinations, and kits containing the modified polypeptide and methods of using the modified polypeptide. Also described herein are methods of using the modified polypeptide as screening agents for the identification and design of inhibitors of PLCy2.
摘要翻译：本文描述了赋予对用BTK抑制剂治疗的抗性的突变。本文描述的是在氨基酸位置742,845或1140修饰的修饰的PLCy2多肽，并且修饰的PLCy2多肽对共价和/或不可逆的BTK抑制剂表现出降低的抑制（例如抗性）。本文描述了用于检测修饰的多肽和编码经修饰的多肽的核酸的诊断方法及其方法的应用。本文描述的是含有修饰多肽的组合物，组合和试剂盒，以及使用修饰多肽的方法。本文还描述了使用修饰的多肽作为用于鉴定和设计PLCy2的抑制剂的筛选剂的方法。

143. 发明申请

WO2015131274A1 REDUCTION OF TRAFL LEVELS COMBINED WITH NUTRIENT STRESS FOR TREATING LYMPHOCYTE-RELATED CANCERS 审中-公开
标题翻译：减少与治疗淋巴细胞相关癌症的营养应激相结合的TRAFL水平
公开(公告)号：WO2015131274A1
公开(公告)日：2015-09-11
申请号：PCT/CA2015/000144
申请日：2015-03-06
申请人： THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO , UNIVERSITY HEALTH NETWORK
发明人： ABDUL SATER, Ali , MCPHERSON, Ann Josephine , WATTS, Tania Helen , MINDEN, Mark , LAISTER, Rob
IPC分类号： A61K38/50 , A61K31/713 , A61K39/395 , A61P35/02 , A61P35/04 , G01N33/48
CPC分类号： A61K38/465 , A61K31/7088 , A61K31/713 , A61K38/50 , A61K45/06 , C12N15/1137 , C12N2310/122 , C12N2320/31 , C12Y305/01001 , C12Y305/03001 , G01N33/502 , G01N33/57407 , G01N33/57426 , G01N2333/525 , A61K2300/00
摘要： The present disclosure provides methods and uses for treating lymphocyte related cancers comprising administering a nutrient stress-inducing agent in combination with an agent that lowers the levels of or inhibits TRAF1. Also provided are methods of determining treatment for a subject with a lymphocyte related cancer and assays for identifying a PKN1 inhibitor.
摘要翻译：本公开提供了治疗淋巴细胞相关癌症的方法和用途，包括与降低TRAF1水平或抑制TRAF1的药剂组合施用营养应激诱导剂。还提供了确定具有淋巴细胞相关癌症的受试者的治疗方法和用于鉴定PKN1抑制剂的测定法。

144. 发明申请

WO2015127172A1 THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE 审中-公开
标题翻译：治疗活性化合物及其使用方法
公开(公告)号：WO2015127172A1
公开(公告)日：2015-08-27
申请号：PCT/US2015/016766
申请日：2015-02-20
申请人： AGIOS PHARMACEUTICALS, INC.
发明人： AGRESTA, Samuel, V. , PRAHL, Malia, Ann
IPC分类号： A61P35/02
CPC分类号： A61K45/06 , A61K31/4439 , G01N33/57426 , G01N2800/52 , A61K2300/00
摘要： Provided are compounds useful for treating cancer and methods of treating cancer comprising administering to a subject in need thereof a compound described herein. Disclosed herein are methods of treating advanced hematologic malignancies characterized by the presence of a mutant allele of IDH1. In one embodiment, the mutant IDHI has an R132X mutation. In one embodiment, the R132X mutation is selected from R132H, R132C, R132L, R132V, R132S and R132G. In some embodiments, the advanced hematologic malignancies harbor a comutation, e.g., a co-mutation selected from NPM1, FLT3, TET2, CEBPA, DNMT3A, and MLL. In one aspect, the present invention provides a method of evaluating a subject, the method comprising: acquiring a value for the level of a compound (S)-N-((S)-1-(2-chlorophenyl)-2-((3,3
摘要翻译：提供的是用于治疗癌症的化合物和治疗癌症的方法，包括向有需要的受试者施用本文所述的化合物。本文公开了治疗晚期血液恶性肿瘤的方法，其特征在于存在IDH1的突变等位基因。在一个实施方案中，突变体IDHI具有R132X突变。在一个实施方案中，R132X突变选自R132H，R132C，R132L，R132V，R132S和R132G。在一些实施方案中，先进的血液恶性肿瘤包含调节，例如选自NPM1，FLT3，TET2，CEBPA，DNMT3A和MLL的共突变。一方面，本发明提供评估受试者的方法，所述方法包括：获得化合物（S）-N - （（S）-1-（2-氯苯基）-2-（（3,3'重氢氟代丁基）am 5HDX-吡咯烷-2-甲酰胺（化合物1）或α羟基新生物产物的水平，例如2HG，例如R-2HG（2HG）。

145. 发明申请

WO2015097536A2 ANTI-VISTA ANTIBODIES AND FRAGMENTS 审中-公开
标题翻译：抗 - VISTA抗体和片段
公开(公告)号：WO2015097536A2
公开(公告)日：2015-07-02
申请号：PCT/IB2014/002868
申请日：2014-12-22
申请人： JANSSEN PHARMACEUTICAL NV
发明人： SNYDER, Linda , POWERS, Gordon
IPC分类号： C07K16/28
CPC分类号： C07K16/2827 , A61K39/39558 , A61K45/06 , A61K2039/505 , C07K16/3015 , C07K16/3023 , C07K16/3038 , C07K2317/21 , C07K2317/24 , C07K2317/33 , C07K2317/34 , C07K2317/51 , C07K2317/515 , C07K2317/52 , C07K2317/55 , C07K2317/56 , C07K2317/565 , C07K2317/567 , C07K2317/732 , C07K2317/74 , C07K2317/75 , C07K2317/76 , C07K2317/92 , G01N33/57426 , G01N33/5743 , G01N33/57492
摘要： The present invention relates to novel antibodies and fragments that bind to a V-domain Ig Suppressor of T cell Activation (VISTA), and methods of making and using same. Methods of use include methods of treatment of cancer, including leukemias, lymphomas, solid tumors and melanomas.
摘要翻译：本发明涉及与T细胞活化的V域Ig抑制子（VISTA）结合的新型抗体和片段，以及制备和使用其的方法。使用方法包括治疗癌症的方法，包括白血病，淋巴瘤，实体瘤和黑素瘤。

146. 发明申请

WO2015084166A1 LEUKEMIC STEM CELL MARKERS 审中-公开
公开(公告)号：WO2015084166A1
公开(公告)日：2015-06-11
申请号：PCT/NL2014/050821
申请日：2014-12-02
申请人： STICHTING VU-VUMC
发明人： OSSENKOPPELE, Gerrit Johan , SCHUURHUIS, Gerrit Jan , ZEIJLEMAKER, Wendelien
IPC分类号： G01N33/574
CPC分类号： G01N33/57426 , G01N15/14 , G01N33/5011 , G01N33/5073 , G01N33/57492 , G01N2015/0065 , G01N2015/1006 , G01N2015/149 , G01N2800/52
摘要： The present invention relates to a method for identifying Leukemic stem cells (LSC), based on measurement of the presence of a specific set of markers. The invention further relates to a container for use in performing the method. Also provided is application of the method for predicting response to therapy and/or chance of relapse of Acute Myeloid Leukemia, and application of the method in the context of screening for compounds that specifically eradicate Leukemic cells and not benign cells.
摘要翻译：本发明涉及一种用于鉴别白血病干细胞（LSC）的方法，该方法是基于特定标记物组的存在的测量。本发明还涉及一种用于执行该方法的容器。还提供了预测对急性骨髓性白血病的治疗反应和/或复发机率的方法的应用，以及在筛选特异性根除白血病细胞而不是良性细胞的化合物的上下文中应用该方法。

147. 发明申请

WO2015017113A3 TUMOR SELECTIVE ANTIBODIES SPECIFIC TO ONCOFETAL ANTIGEN / IMMATURE LAMININ RECEPTOR PROTEIN 审中-公开
标题翻译：肿瘤选择性抗体特异性在线抗原/免疫层粘连蛋白受体蛋白
公开(公告)号：WO2015017113A3
公开(公告)日：2015-04-09
申请号：PCT/US2014046424
申请日：2014-07-11
申请人： BENOVUS BIO INC , UNIV SOUTH ALABAMA
发明人： JOHNSON KENT J , MORGAN ALTON C , VARANI JAMES , ROHRER JAMES W , BARSOUM ADEL L , SINKULE JOSEPH A , COGGIN JOSEPH H JR
IPC分类号： C07K16/28 , A61K39/00 , A61P35/00 , A61P35/04 , C07K16/30
CPC分类号： C07K16/30 , A61K2039/505 , C07K16/3015 , C07K16/3023 , C07K16/303 , C07K16/3046 , C07K16/3061 , C07K16/3069 , C07K2317/20 , C07K2317/33 , C07K2317/34 , C07K2317/565 , C07K2317/73 , C07K2317/76 , C07K2317/92 , G01N33/57426 , G01N33/57476 , G01N2333/705
摘要： Disclosed are high affinity antibodies or antigen binding fragments thereof, which bind an epitope that lies within the C terminal region of oncofetal antigen (OFA)/immature laminin receptor protein (iLRP), and which do not substantially cross-react with mature OFA/LRP. The antibodies may be conjugated to cytotoxic moieties to enhance their therapeutic efficacy. Methods of making the antibodies and therapeutic and diagnostic uses thereof are also disclosed.
摘要翻译：公开了高亲和力抗体或其抗原结合片段，其结合位于癌胚抗原（OFA）/未成熟层粘连蛋白受体蛋白（iLRP）的C末端区域内的表位，并且其基本上不与成熟OFA / LRP交叉反应。抗体可以缀合至细胞毒性部分以增强其治疗功效。还公开了制备抗体的方法及其治疗和诊断用途。

148. 发明申请

WO2015028484A1 ANTIBODIES FOR DIAGNOSIS OF ACUTE MYELOID LEUKEMIA 审中-公开
标题翻译：用于诊断急性髓性白血病的抗体
公开(公告)号：WO2015028484A1
公开(公告)日：2015-03-05
申请号：PCT/EP2014/068116
申请日：2014-08-27
申请人： FRAUNHOFER-GESELLSCHAFT ZUR FÖRDERUNG DER ANGEWANDTEN FORSCHUNG E.V.
发明人： BARTH, Stefan , TUR, Mehmet Kemal , FITTING, Jenny
IPC分类号： C07K16/18 , C07K16/30
CPC分类号： C07K16/30 , C07K2317/33 , C07K2317/565 , C07K2317/622 , C07K2317/92 , G01N33/57426
摘要： A polypeptide in particular an antibody or antibody fragment is disclosed wherein the polypeptide is corresponding to certain complementarity determining regions CDR1, CDR2 and CDR3 of a heavy chain V H and a light chain V L of an antibody as well as a compound comprising the polypeptide, its use as diagnostic agent for acute myeloid leukemia subtype M2 and a kit comprising the compound.
摘要翻译：公开了多肽，特别是抗体或抗体片段，其中多肽对应于重链VH和抗体的轻链VL的某些互补决定区CDR1，CDR2和CDR3以及包含该多肽的化合物，其用途作为急性骨髓性白血病亚型M2的诊断剂和包含该化合物的试剂盒。

149. 发明申请

WO2015023866A1 METHODS AND BIOMARKERS FOR DETECTION AND TREATMENT OF MATURE T-CELL LEUKEMIA 审中-公开
标题翻译：用于检测和治疗成熟T细胞淋巴细胞的方法和生物标志物
公开(公告)号：WO2015023866A1
公开(公告)日：2015-02-19
申请号：PCT/US2014/051099
申请日：2014-08-14
申请人： THE REGENTS OF THE UNIVERSITY OF MICHIGAN
发明人： ELENITOBA-JOHNSON, Kojo , KIEL, Mark J. , VELUSAMY, Thirunavukkarasu , SAHASRABUDDHE, Anagh , ROLLAND, Delphine , LIM, Megan
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6886 , C12Q2600/118 , C12Q2600/156 , G01N33/57426 , G01N2333/91205 , G01N2800/52
摘要： The present invention relates to methods and biomarkers for detection and characterization of mature T-cell neoplasias / leukemias (e.g., T-cell prolymphocytic leukemia, Sezary syndrome) in biological samples (e.g., tissue samples, blood samples, plasma samples, cell samples, serum samples).
摘要翻译：本发明涉及用于生物样品（例如，组织样品，血液样品，血浆样品，细胞样品，血液样品，血液样品，血液样品，血清样品）。

150. 发明申请

WO2015017113A2 TUMOR SELECTIVE ANTIBODIES SPECIFIC TO ONCOFETAL ANTIGEN / IMMATURE LAMININ RECEPTOR PROTEIN 审中-公开
标题翻译：肿瘤选择性抗体特异性在线抗原/免疫层粘连蛋白受体蛋白
公开(公告)号：WO2015017113A2
公开(公告)日：2015-02-05
申请号：PCT/US2014/046424
申请日：2014-07-11
申请人： BENOVUS BIO, INC. , SOUTH ALABAMA MEDICAL SCIENCE FOUNDATION
发明人： JOHNSON, Kent J. , MORGAN, Alton C. , VARANI, James , ROHRER, James W. , BARSOUM, Adel L.
IPC分类号： A61K39/395
CPC分类号： C07K16/30 , A61K2039/505 , C07K16/3015 , C07K16/3023 , C07K16/303 , C07K16/3046 , C07K16/3061 , C07K16/3069 , C07K2317/20 , C07K2317/33 , C07K2317/34 , C07K2317/565 , C07K2317/73 , C07K2317/76 , C07K2317/92 , G01N33/57426 , G01N33/57476 , G01N2333/705
摘要： Disclosed are high affinity antibodies or antigen binding fragments thereof, which bind an epitope that lies within the C terminal region of oncofetal antigen (OFA)/immature laminin receptor protein (iLRP), and which do not substantially cross-react with mature OFA/LRP. The antibodies may be conjugated to cytotoxic moieties to enhance their therapeutic efficacy. Methods of making the antibodies and therapeutic and diagnostic uses thereof are also disclosed.
摘要翻译：公开了高亲和力抗体或其抗原结合片段，其结合位于癌周抗原（OFA）/未成熟层粘连蛋白受体蛋白（iLRP）的C末端区域内的表位，并且其基本上不表达与成熟的OFA / LRP交叉反应。抗体可以缀合至细胞毒性部分以增强其治疗功效。还公开了制备抗体的方法及其治疗和诊断用途。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式